We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technology



There is a cure for autoimmune diabetes

What We Do

We develop therapies using our in-licensed substances GAD, GABA and Gliadin for the prevention or treatment of autoimmune diabetes

Diamyd Medical is a Swedish diabetes company active in the field of pharmaceutical development. Diamyd Medical’s shares are traded on Nasdaq Stockholm First North, ticker DMYD B.

Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based Therapy (ABT) based on the exclusively in-licensed GAD molecule. In-licensed technologies for GABA and Gliadin also have the potential to become key pieces in the puzzle of a future solution to prevent, treat or cure autoimmune diabetes and other inflammation-related conditions.



415 million people worldwide suffer from diabetes. 10-20 percent have autoimmune diabetes (type 1 diabetes and LADA). There is currently no available preventive treatment or cure.



Diamyd Medical tackles autoimmune diabetes (type 1 diabetes and LADA) on three fronts: drug development, stem cell and medical technology. Six clinical trials are ongoing, combining the diabetes vaccine Diamyd® with various other immunomodulatory compounds including GABA.


Diamyd Medical is a cost-efficient and flexible company with substantial experience of pharmaceutical and technical development. Parts of the operations are outsourced to qualified partners with expert knowledge while the company employees manage and implement clinical and preclinical development, regulatory affairs, production and business development.


Opinion makers in the field clearly advocate studies that are in line with Diamyd Medical’s development strategy.

Ulf Hannelius
President and CEO, Diamyd Medical AB